本文選題：CD147 + MMP-2��； 參考：《天津醫(yī)科大學(xué)》2014年碩士論文

【摘要】：背景與目的：前列腺癌(Prostate carcinoma,PCa)是男性泌尿系統(tǒng)中比較常見的惡性腫瘤,在世界范圍內(nèi)的發(fā)病率占男性所有惡性腫瘤的第二位,是西方國家最常見的泌尿系統(tǒng)腫瘤,在我國的發(fā)病率也呈現(xiàn)出逐年上升的趨勢。外科手術(shù)或者內(nèi)分泌治療是目前最為有效的治療措施,但仍容易復(fù)發(fā)和轉(zhuǎn)移,嚴(yán)重影響患者的預(yù)后生存。前列腺癌的發(fā)病機制至今仍未闡明。因其臨床癥狀較為隱匿、自然病程也較長,普查未完全普及,許多的患者確診時已發(fā)展到了晚期。近年來研究證明,CD147、MMP-2與腫瘤的發(fā)生和發(fā)展存在著密切的關(guān)系,本實驗通過免疫組化的方法檢測CD147和MMP-2在前列腺癌組織中表達(dá),分析CD147和MMP-2在前列腺癌癌組織中的表達(dá)與腫瘤的分化程度、臨床分期、有無轉(zhuǎn)移、年齡、PSA等因素之間的關(guān)系及其相關(guān)性。探討兩者在前列腺癌的發(fā)生以及發(fā)展過程中作用,為臨床診斷及監(jiān)測預(yù)后提供參考依據(jù)。 資料與方法：選取天津醫(yī)科大學(xué)第二醫(yī)院2010年3月-2013年3月間前列腺疾病的石蠟包埋標(biāo)本90例,其中前列腺癌標(biāo)本60例,年齡58-81歲,平均67歲；良性前列腺增生標(biāo)本30例,年齡55-82歲,平均65歲。兩組間年齡差異無統(tǒng)計學(xué)意義。根據(jù)前列腺癌危險因素等級再進行分組,按Gleason分級低中危(2-7分)24例,高危(8-10分)36例；按TNM分期,T1-T2b期29例,T2c-T4期31例；PSA≤20ng/ml25例,PSA20ng/m135例；發(fā)生淋巴結(jié)轉(zhuǎn)移者32例,無淋巴結(jié)轉(zhuǎn)移者28例。所有患者術(shù)前都沒有接受放療、化療或者內(nèi)分泌治療。實驗采用鏈霉菌素抗生物素蛋白-過氧化物酶免疫組化法(streptavidin-peroxidase, SP法)進行檢測。染色步驟按照試劑盒的說明書分別進行,選用乳腺癌已知MMP-2和CD147陽性組織切片作為陽性對照,用PBS液代替一抗作為陰性對照。MMP-2陽性表達(dá)主要表現(xiàn)為在細(xì)胞漿出現(xiàn)棕色或者棕黃色顆粒,CD147陽性表達(dá)主要表現(xiàn)為在細(xì)胞膜或細(xì)胞漿中出現(xiàn)棕色或者棕黃色顆粒,用陽性細(xì)胞的標(biāo)記個數(shù)結(jié)合染色強度來綜合判斷染色結(jié)果。應(yīng)用SPSS19.0統(tǒng)計軟件包對所有數(shù)據(jù)進行統(tǒng)計學(xué)分析。P0.05代表差異有統(tǒng)計學(xué)意義。 結(jié)果：(1)在60例前列腺癌組織中,有41例呈CD147的陽性表達(dá),陽性表達(dá)率為68.3%；而在30例良性前列腺增生的組織中,有4例呈陽性表達(dá),陽性表達(dá)率為13.3%。前列腺癌組和良性前列腺增生組進行比較,差異具有統(tǒng)計學(xué)意義,P0.01。CD147在前列腺癌細(xì)胞中的陽性表達(dá)率顯著高于良性前列腺增生組。(2)在60例前列腺癌組織中,有46例呈MMP-2的陽性表達(dá),陽性表達(dá)率為76.7%；而在30例良性前列腺增生組織中,陽性表達(dá)有3例,陽性率為10.0%。前列腺癌組和良性前列腺增生組進行比較,差異有統(tǒng)計學(xué)意義,P0.01。MMP-2在前列腺癌細(xì)胞中的陽性表達(dá)率顯著高于良性前列腺增生組。(3)在60例前列腺癌組織中,MMP-2和CD147的陽性表達(dá)與患者的PSA和年齡無關(guān),其陽性表達(dá)率在不同PSA和不同年齡患者中差異無統(tǒng)計學(xué)意義,P0.05。但是在不同的病理分級、臨床分期及有無轉(zhuǎn)移的患者中表達(dá)具有統(tǒng)計學(xué)意義,P0.05。有轉(zhuǎn)移的患者標(biāo)本MMP-2和CD147陽性表達(dá)率要高于無轉(zhuǎn)移的患者；Glesaon評分高及TNM分期高的患者中MMP-2和CD147陽性表達(dá)率也較高。(4)在60例前列腺癌組織中,其中有37例同時表達(dá)MMP-2和CD147,而同為陰性者有10例,經(jīng)Spearman相關(guān)分析表明,MMP-2和CD147在前列腺癌組織中表達(dá)呈正相關(guān)(r=0.472,P0.01) 結(jié)論：(1)研究顯示CD147和MMP-2在前列腺癌組織中的表達(dá)明顯上調(diào),且與良性前列腺增生組織相比較差異有統(tǒng)計學(xué)意義,提示CD147和MMP-2可能參與前列腺癌的發(fā)生。(2)CD147和MMP-2在前列腺癌組織中的表達(dá)與腫瘤的病理分級、臨床分期和是否轉(zhuǎn)移密切相關(guān),與年齡及PSA無關(guān)。CD147和MMP-2高表達(dá)者其腫瘤的惡性程度也較高,侵襲性較強,更具有轉(zhuǎn)移的傾向。提示CD147和MMP-2可能參與前列腺癌的進展以及擴散轉(zhuǎn)移。(3)在前列腺癌組織中,CD147和MMP-2的表達(dá)呈顯著正相關(guān),兩者可能在前列腺癌的發(fā)生、發(fā)展及轉(zhuǎn)移過程中起著協(xié)同作用。(4)CD147和MMP-2蛋白表達(dá)的聯(lián)合檢測可以對前列腺癌的發(fā)生、發(fā)展、預(yù)后及藥物治療提供重要的參考依據(jù)。
[Abstract]:Background and purpose: Prostate carcinoma (PCa) is the most common malignant tumor in the male urinary system. The incidence of the disease in the world accounts for second of all male malignant tumors. It is the most common urological tumor in the western countries, and the incidence of the disease is also rising year by year in our country. Secretory therapy is the most effective treatment at present, but it is still prone to recurrence and metastasis, which seriously affects the survival of the patients. The pathogenesis of prostate cancer has still not been clarified. Because of its clinical symptoms are concealed, the natural course is long, the general survey is not completely popularized, and many patients have been developed to the late stage. In recent years, the research has proved that CD147 and MMP-2 are closely related to the development and development of tumors. In this experiment, the expression of CD147 and MMP-2 in prostate cancer tissues was detected by immunohistochemical method. The expression of CD147 and MMP-2 in the cancer tissues of the prostate and the degree of differentiation of the tumor, the clinical stages, the relationship between the metastasis, age, and PSA and other factors were analyzed. Objective to explore the role of both in the occurrence and development of prostate cancer, so as to provide reference for clinical diagnosis and prognosis.
Materials and methods: 90 cases of paraffin embedded specimens of prostate disease in Second Hospital Affiliated to Tianjin Medical University in March -2013 March 2010 were selected, including 60 cases of prostate cancer, 58-81 years old and 67 years old, 30 cases of benign prostatic hyperplasia, 55-82 years old, with an average of 65 years. The age difference between the two groups was not statistically significant. According to the prostate cancer, the prostate cancer was not statistically significant. Risk factors were divided into groups, 24 cases of low medium risk (2-7 points) and 36 cases at high risk (8-10 points) according to Gleason classification, TNM staging, 29 cases of T1-T2b, 31 cases of T2c-T4, PSA < 20ng/ml25, PSA20ng/m135 cases, 32 cases of lymph node metastasis, and 28 cases without lymph node metastasis. All patients were not treated with radiotherapy, chemotherapy, or endocrinology before operation. The test was carried out by Streptomyces anti biotin peroxidase immunohistochemical method (streptavidin-peroxidase, SP). The staining steps were carried out according to the instructions of the kit, and the positive control of the breast cancer MMP-2 and CD147 positive tissue sections was selected, and the PBS solution was used instead of the negative control.MMP-2 positive table. The main manifestations were brown or brown granules in cytoplasm. The positive expression of CD147 was brown or brown granules in cell membrane or cytoplasm. The staining results were judged by the number of positive cells combined with the staining intensity. All data were statistically analyzed by the SPSS19.0 software package. P0.05 represents a statistically significant difference.
Results: (1) in 60 cases of prostate cancer, 41 cases showed positive expression of CD147 and the positive expression rate was 68.3%. In 30 cases of benign prostatic hyperplasia, 4 cases showed positive expression, the positive rate was compared with the 13.3%. prostate cancer group and the benign prostatic hyperplasia group, the difference was statistically significant, P0.01.CD147 was in the prostate. The positive expression rate in the cancer cells was significantly higher than that in the benign prostatic hyperplasia group. (2) in 60 cases of prostate cancer, 46 cases showed positive expression of MMP-2 and the positive expression rate was 76.7%. In 30 cases of benign prostatic hyperplasia, the positive expression was 3 cases, the positive rate was compared with the anterior 10.0%. adenocarcinoma group and the benign prostatic hyperplasia group. The positive expression rate of P0.01.MMP-2 in the prostate cancer cells was significantly higher than that in the benign prostatic hyperplasia group. (3) in 60 cases of prostate cancer, the positive expression of MMP-2 and CD147 was not related to the PSA and age of the patients. The positive expression rate was not statistically significant in different PSA and different years of age, but P0.05. was not significant. The expression of the same pathological grading, clinical staging and non metastasis was statistically significant. The positive expression rate of MMP-2 and CD147 in patients with P0.05. metastasis was higher than that of non metastatic patients; the positive expression rate of MMP-2 and CD147 in patients with high Glesaon score and high TNM stage were also higher. (4) among 60 cases of prostate cancer, 37 MMP-2 and CD147 were expressed at the same time, and 10 cases were negative. The Spearman correlation analysis showed that the expression of MMP-2 and CD147 in the prostate cancer tissues was positively correlated (r=0.472, P0.01).
Conclusions: (1) the study showed that the expression of CD147 and MMP-2 in the prostate cancer tissues was significantly up-regulated and compared with the benign prostatic hyperplasia, suggesting that CD147 and MMP-2 may be involved in the occurrence of prostate cancer. (2) the expression of CD147 and MMP-2 in the prostate cancer tissues and the pathological classification of the tumor, clinical stages and whether or not. Metastasis is closely related,.CD147 and high expression of PSA are not related to age and MMP-2, with higher malignancy, stronger invasiveness and more metastatic tendency. It suggests that CD147 and MMP-2 may be involved in the progression of prostate cancer and metastasis. (3) in prostate cancer, the expression of CD147 and MMP-2 is positively correlated, and both may be in the front of the prostate cancer. There is a synergistic effect in the occurrence, development and metastasis of adenocarcinoma. (4) the combined detection of CD147 and MMP-2 protein expression can provide important reference for the development, development, prognosis and drug treatment of prostate cancer.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.25

【參考文獻】

相關(guān)期刊論文 前10條

1 韓蘇軍;張思維;陳萬青;李長嶺;;中國前列腺癌發(fā)病現(xiàn)狀和流行趨勢分析[J];臨床腫瘤學(xué)雜志;2013年04期

2 楊萬廣;王萬鵬;張謝夫;;ALDH1A2、MMP2和E-cadherin在結(jié)腸癌組織中的表達(dá)及相關(guān)性[J];世界華人消化雜志;2013年04期

3 彭鵬;龔楊明;鮑萍萍;柯居中;向奰梅;張敏璐;鄭瑩;;中國2008年前列腺癌發(fā)病、死亡和患病情況的估計及預(yù)測[J];中華流行病學(xué)雜志;2012年10期

4 聶珍琳;唐志鵬;王書奎;;CD147在腫瘤診斷、治療及預(yù)后判斷中的作用研究進展[J];國際檢驗醫(yī)學(xué)雜志;2012年06期

5 戴奇山;王月生;畢學(xué)成;韓兆冬;葉永康;何慧嬋;鐘惟德;;CD147在前列腺癌組織中陽性表達(dá)與PSA失敗的相關(guān)性分析[J];嶺南現(xiàn)代臨床外科;2010年04期

6 王祥軍;吳新勇;何長青;蔡安慶;;CD147和MMP-9在乳腺癌中的表達(dá)及其與微血管生成的相關(guān)性研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2010年07期

7 馮銘恩;馮亮;;STAT3及CD147在前列腺癌中的表達(dá)研究[J];南昌大學(xué)學(xué)報(醫(yī)學(xué)版);2010年03期

8 張鶴鵬;俞斌;鄭旭東;胡華杰;高志斌;李莉;周麗芳;;膀胱移行細(xì)胞癌組織環(huán)氧化酶2和基質(zhì)金屬蛋白酶2 mRNA的表達(dá)及相關(guān)性[J];中華男科學(xué)雜志;2008年11期

9 韓寒;劉克良;;基質(zhì)金屬蛋白酶抑制劑研究進展[J];國際藥學(xué)研究雜志;2008年03期

10 Satoshi Mamori;Keisuke Nagatsuma;Tomokazu Matsuura;Kiyoshi Ohkawa;Hiroshi Hano;Masaharu Fukunaga;Masato Matsushima;Yoshifumi Masui;Nao Fushiya;Hiroshi Onoda;Yasuyuki Searashi;Ichiro Takagi;Hisao Tajiri;;Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples[J];World Journal of Gastroenterology;2007年21期

，

本文編號：1916330